Brexpiprazole

CAT#: H317111

CAS#:

Description: Brexpiprazole, also known as OPC-34712, is a novel D2 dopamine partial agonist called serotonin-dopamine activity modulator (SDAM) approved for the treatment of schizophrenia, and as an adjunctive treatment for depression. Although it failed Phase II clinical trials for ADHD, it has been designed to provide improved efficacy and tolerability (e.g., less akathisia, restlessness and/or insomnia) over established adjunctive treatments for major depressive disorder (MDD). Brexpiprazole was approved on 7/10/2015.

img

Synthetic Routes

Brexpiprazole - Synthetic Route 1

Brexpiprazole route01

Synthetic reference

Brexpiprazole - Synthetic Route 2

Brexpiprazole route02

Synthetic reference

Brexpiprazole - Synthetic Route 3

Brexpiprazole route03

Synthetic reference

Brexpiprazole - Synthetic Route 4

Brexpiprazole route04

Synthetic reference

Brexpiprazole - Synthetic Route 5

Brexpiprazole route05

Synthetic reference

Brexpiprazole - Synthetic Route 6

Brexpiprazole route06

Synthetic reference

Brexpiprazole - Synthetic Route 7

Brexpiprazole route07

Synthetic reference

Brexpiprazole - Synthetic Route 8

Brexpiprazole route08

Synthetic reference

Brexpiprazole - Synthetic Route 9

Brexpiprazole route09

Synthetic reference

Brexpiprazole - Synthetic Route 10

Brexpiprazole route010

Synthetic reference

Chen, Weiming; Suo, Jin; Liu, Yongjian; Xie, Yuanchao; Wu, Mingjun; Zhu, Fuqiang; Nian, Yifeng; Aisa, Haji A.; Shen, Jingshan. Industry-Oriented Route Evaluation and Process Optimization for the Preparation of Brexpiprazole. Organic Process Research & Development. Volume 23. Issue 5. Pages 852-857. 2019.